SINGAPORE (Oct 22): Recently, Sandoz, the generics division of Novartis, settled a patent lawsuit with AbbVie over Humira, a so-called biologic drug that treats rheumatoid arthritis and just so happens to be the biggest money-maker in all of pharma. With 2017 sales of US$18.4 billion ($25.3 billion), Humira accounts for an astonishing 65% of AbbVie’s revenue.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $4.99/month*

The latest reporting and analysis from business and investments to news and views on social issues.

Bonus:

  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply

Subscribe